Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Asymmetric cancer cell division regulated by AKT.

Dey-Guha I, Wolfer A, Yeh AC, G Albeck J, Darp R, Leon E, Wulfkuhle J, Petricoin EF 3rd, Wittner BS, Ramaswamy S.

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12845-50. doi: 10.1073/pnas.1109632108. Epub 2011 Jul 14.

2.
3.

A mechanism for asymmetric cell division resulting in proliferative asynchronicity.

Dey-Guha I, Alves CP, Yeh AC, Salony, Sole X, Darp R, Ramaswamy S.

Mol Cancer Res. 2015 Feb;13(2):223-30. doi: 10.1158/1541-7786.MCR-14-0474. Epub 2015 Jan 12.

4.

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL.

Mol Cancer Ther. 2015 Nov;14(11):2441-51. doi: 10.1158/1535-7163.MCT-15-0230. Epub 2015 Sep 8.

5.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

6.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

8.

Induction of cellular apoptosis in human breast cancer by DLBS1425, a Phaleria macrocarpa compound extract, via down-regulation of PI3-kinase/AKT pathway.

Tandrasasmita OM, Lee JS, Baek SH, Tjandrawinata RR.

Cancer Biol Ther. 2010 Oct 15;10(8):814-23. doi: 10.4161/cbt.10.8.13085. Epub 2010 Oct 15.

PMID:
20703095
9.

AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.

Salony, Solé X, Alves CP, Dey-Guha I, Ritsma L, Boukhali M, Lee JH, Chowdhury J, Ross KN, Haas W, Vasudevan S, Ramaswamy S.

Mol Cancer Ther. 2016 Jan;15(1):142-53. doi: 10.1158/1535-7163.MCT-15-0414. Epub 2015 Dec 4.

10.

PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells.

Luo H, Yang Y, Duan J, Wu P, Jiang Q, Xu C.

Cell Death Dis. 2013 Feb 7;4:e481. doi: 10.1038/cddis.2013.3.

11.

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.

12.

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.

Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):19-31. doi: 10.1007/s00210-014-1032-y. Epub 2014 Aug 28.

PMID:
25164962
13.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

14.

Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells.

Rajput S, Kumar BN, Dey KK, Pal I, Parekh A, Mandal M.

Life Sci. 2013 Nov 13;93(21):783-90. doi: 10.1016/j.lfs.2013.09.009. Epub 2013 Sep 15.

PMID:
24044882
15.

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N.

Cancer Cell. 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. Epub 2011 Jan 6.

16.

KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.

Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S, Meng J, Ji L, Coombes K, Minna JD, Fang B, Roth JA.

Cancer Res. 2013 Sep 1;73(17):5532-43. doi: 10.1158/0008-5472.CAN-13-0712. Epub 2013 Jul 3.

17.

Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.

Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J.

PLoS One. 2014 Mar 11;9(3):e91245. doi: 10.1371/journal.pone.0091245. eCollection 2014.

18.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

19.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.

20.

Deltonin induces apoptosis in MDA‑MB‑231 human breast cancer cells via reactive oxygen species‑mediated mitochondrial dysfunction and ERK/AKT signaling pathways.

Zhang S, He Y, Tong Q, Chen Q, Wu X, Huang W.

Mol Med Rep. 2013 Mar;7(3):1038-44. doi: 10.3892/mmr.2013.1273. Epub 2013 Jan 11.

PMID:
23314115

Supplemental Content

Support Center